Literature DB >> 23943725

Aspirin and salicylate in respiratory disease.

J E Mitchell1, I Skypala.   

Abstract

This article describes the natural history, pathogenesis and diagnosis of Aspirin Exacerbated Respiratory Disease. The evidence base for the role of oral aspirin and nasal L-Lysine-aspirin desensitisation is reviewed. Evidence for the role of dietary salicylic acid and its avoidance is also reviewed.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23943725     DOI： 10.4193/Rhino12.144

Source DB:  PubMed          Journal:  Rhinology        ISSN： 0300-0729            Impact factor:   3.681


  7 in total

Review 1.  Update on Aspirin-Exacerbated Respiratory Disease.

Authors:  Katharine M Woessner
Journal:  Curr Allergy Asthma Rep       Date:  2017-01       Impact factor: 4.806

Review 2.  Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations.

Authors:  Joshua M Levy; Luke Rudmik; Anju T Peters; Sarah K Wise; Brian W Rotenberg; Timothy L Smith
Journal:  Int Forum Allergy Rhinol       Date:  2016-08-02       Impact factor: 3.858

Review 3.  Aspirin-exacerbated respiratory disease and current treatment modalities.

Authors:  Emine Güven Sakalar; Nuray Bayar Muluk; Murat Kar; Cemal Cingi
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-18       Impact factor: 2.503

4.  No significant detectable anti-infection effects of aspirin and statins in chronic obstructive pulmonary disease.

Authors:  Josef Yayan
Journal:  Int J Med Sci       Date:  2015-03-02       Impact factor: 3.738

5.  The development of a standardised diet history tool to support the diagnosis of food allergy.

Authors:  Isabel J Skypala; Carina Venter; Rosan Meyer; Nicolette W deJong; Adam T Fox; Marion Groetch; J N Oude Elberink; Aline Sprikkelman; Louiza Diamandi; Berber J Vlieg-Boerstra
Journal:  Clin Transl Allergy       Date:  2015-02-19       Impact factor: 5.871

Review 6.  Sensitivity to food additives, vaso-active amines and salicylates: a review of the evidence.

Authors:  Isabel J Skypala; M Williams; L Reeves; R Meyer; C Venter
Journal:  Clin Transl Allergy       Date:  2015-10-13       Impact factor: 5.871

7.  Broncalt®, class II medical device, in patients with acute upper airways disease: a survey in clinical practice.

Authors:  Gian Franco Cupido; Matteo Gelardi; Ignazio La Mantia; Salvo Emanuele Aragona; Claudio Vicini; Giorgio Ciprandi; Italian Study Group On Inflammatory Otorhinolaryngological Disorders
Journal:  Acta Biomed       Date:  2019-07-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.